Publicaciones en las que colabora con Esperanza Merino de Lucas (8)

2024

  1. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients

    International Journal of Infectious Diseases, Vol. 144

2021

  1. Propensity score and desirability of outcome ranking analysis of ertapenem for treatment of nonsevere bacteremic urinary tract infections due to extended-spectrum-beta-lactamase-producing enterobacterales in kidney transplant recipients

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 11

2018

  1. Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation

    Clinical Microbiology and Infection, Vol. 24, Núm. 2, pp. 192-198

2017

  1. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey

    Transplant Infectious Disease, Vol. 19, Núm. 6

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study

    American Journal of Transplantation, Vol. 16, Núm. 11, pp. 3220-3234

  2. Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case–Control Study

    American Journal of Transplantation, Vol. 16, Núm. 7, pp. 2148-2157

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784